Log in to search using one of your social media accounts:

 

Paper of note in Science Translational Medicine 9 (406)
This week’s article describes how targeted antimicrobials may reduce the virulence of Clostridium difficile infection. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - September 12, 2017 Category: Science Authors: Ferrarelli, L. K. Tags: STKE Editors ' Choice Source Type: news

Summit Therapeutics secures $62m contract to develop ridinilazole for CDI treatment
UK-based drug discovery and development company Summit Therapeutics has secured a contract worth up to $62m to support the clinical and regulatory development of ridinilazole for the treatment of C. difficile infection (CDI). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 11, 2017 Category: Pharmaceuticals Source Type: news

Early Fecal Transplant Improves Survival After Severe C diff Infection Early Fecal Transplant Improves Survival After Severe C diff Infection
Patients with severe Clostridium difficile infection (CDI) who receive early fecal microbiota transplant (FMT) have improved survival, researchers from France report.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - September 7, 2017 Category: Surgery Tags: Gastroenterology News Source Type: news

BREAKTHROUGH as certain probiotics are found to produce powerful antibiotics that kill superbugs
(Natural News) Scientists at the Baylor College of Medicine are saying that next-generation probiotics can reduce the risk of becoming infected with the bacterium Clostridium difficile, also known a C. difficile or C. diff. This is a common bacterial infection which causes gastrointestinal issues such as bowel discomfort and diarrhea. Treatment for the condition usually... (Source: NaturalNews.com)
Source: NaturalNews.com - August 20, 2017 Category: Consumer Health News Source Type: news

Bezlotoxumab (Zinplava) for Prevention of Recurrent Clostridium Difficile Infection
The FDA has approved the fully human monoclonal antibody bezlotoxumab (Zinplava – Merck) for use with antibacterial drug treatment to reduce recurrence of Clostridium difficile infection (CDI) in adults with CDI at high risk for recurrence. It is the first drug to be approved for this indication. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 18, 2017 Category: Consumer Health News Source Type: news

Research opens possibility of reducing risk of gut bacterial infections with next-generation probiotic
(Baylor College of Medicine) In laboratory-grown bacterial communities, the co-administration of probiotic Lactobacillus reuteri and glycerol selectively killed C. difficile. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 9, 2017 Category: International Medicine & Public Health Source Type: news

Rebiotix starts enrolment in Phase III trial of RBX2660 for C. diff infection
US-based clinical-stage microbiome firm Rebiotix has started patient enrolment in a Phase III clinical trial of RBX2660 to prevent recurrent Clostridium difficile (C. diff) infection. (Source: Drug Development Technology)
Source: Drug Development Technology - August 8, 2017 Category: Pharmaceuticals Source Type: news

MassDevice.com +5 | The top 5 medtech stories for August 8, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Why the medtech contract manufacturing M&A trend isn’t slowing down Consolidation is increasingly shaping the medical device industry, but what about players on the other side of the fence? Medtech contract manufactur...
Source: Mass Device - August 8, 2017 Category: Medical Devices Authors: MassDevice Tags: Blog News Well Plus 5 Source Type: news

Luminex Corporation Receives FDA Clearance for ARIES C. difficile Assay
Sample to answer test provides detection of both toxin A and B AUSTIN, Texas, July 24, 2017 -- (Healthcare Sales & Marketing Network) -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received FDA clearance for the ARIES® C. diffici... Diagnostics, FDA Luminex, ARIES, C. difficile Assay, C. difficile (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 24, 2017 Category: Pharmaceuticals Source Type: news

Medical News Today: Calcium could be the answer to C. difficile infection
Calcium is key in allowing Clostridium difficile to germinate, a new study finds, but it might also be the answer to stopping or slowing down its spread. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 14, 2017 Category: Consumer Health News Tags: Infectious Diseases / Bacteria / Viruses Source Type: news

Could calcium hold the key to fighting a dangerous hospital infection?
(Michigan Medicine - University of Michigan) It lurks in hospitals and nursing homes, preying upon patients already weak from disease or advanced age. It kills nearly 30,000 Americans a year, and sickens half a million more. But new research shows that Clostridium difficile bacteria can't do all this without enough of a humble nutrient: calcium. And that new knowledge may lead to better treatment for the most vulnerable patients. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - July 13, 2017 Category: Infectious Diseases Source Type: news

Health Watch: Sandbox Bacteria Warning
BOSTON (CBS) – It may not be all fun in the sun and sand this summer. That neighborhood sandbox may be a breeding ground for germs. A study out of Spain found that many of the playground sandboxes that they tested contained a bacterium which can cause a bad intestinal infection. The bacterium they were looking for in this small study is C. difficile which can cause a bad intestinal infection. Sandboxes could become contaminated through human and animal waste. Other studies have found parasites and worms in some sandboxes. Does this mean you shouldn’t let your children play in a sandbox? Not necessarily. But sta...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - July 10, 2017 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health Local News Children Health Health Watch playground sandbox Sandbox Bacteria Source Type: news

Recurring Gut Infections on the Rise: Study
Clostridium difficile is the No. 1 health care-linked infection in America, and some people can't shake it (Source: WebMD Health)
Source: WebMD Health - July 7, 2017 Category: Consumer Health News Source Type: news

Recurring Intestinal Infections on The Rise in U.S.: Study
Clostridium difficile is the No. 1 health care-linked infection in America, and some people can't shake it Source: HealthDay Related MedlinePlus Pages: Clostridium Difficile Infections, Diarrhea (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - July 7, 2017 Category: Consumer Health News Source Type: news

Recurring Intestinal Infections on the Rise in U.S.: Study
FRIDAY, July 7, 2017 -- Recurring Clostridium difficile intestinal infections are rising sharply in the United States, researchers warn. These infections sicken about 500,000 people a year, cause tens of thousands of deaths, and cost the U.S.... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 7, 2017 Category: General Medicine Source Type: news

Superbug that lurks sandpit found to contain C. difficile
Tests on sandpits found high levels of a superbug that poses a ‘serious threat’ to children, a study published in the journal Zoonoses and Public Health has found. (Source: the Mail online | Health)
Source: the Mail online | Health - July 7, 2017 Category: Consumer Health News Source Type: news

Clostridium difficile infection WARNING over children's sand pits harbouring superbug
SAND play pits harbour the emerging superbug C. diff that causes stomach upsets and diarrhoea and in rare cases damages the gut, a new study found. (Source: Daily Express - Health)
Source: Daily Express - Health - July 7, 2017 Category: Consumer Health News Source Type: news

Sand in public playgrounds may play a role in transmitting infections
(Wiley) Investigators have revealed that the Gram-positive, anaerobic bacterium Clostridium difficile is widely distributed in soil samples from children's and dogs' sandboxes located within the metropolitan area of Madrid. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 7, 2017 Category: International Medicine & Public Health Source Type: news

Multiply Recurrent C. difficile Infections Rising Sharply (FREE)
By Kelly Young Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM The incidence of multiply recurrent Clostridium difficile infections (CDI) increased faster than regular C. difficile infections in recent years, a study in … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - July 5, 2017 Category: Primary Care Source Type: news

Multiply Recurrent C difficile Infection Rates Sharply Rise Multiply Recurrent C difficile Infection Rates Sharply Rise
Multiply recurrent Clostridium difficile infection rates sharply rose from 2001 to 2012 compared with total C difficile rates.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 3, 2017 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news

Cases of recurrent Clostridium difficile infection are soaring
(University of Pennsylvania School of Medicine) Researchers from the Perelman School of Medicine at the University of Pennsylvania have found evidence that the most difficult C. difficile cases, known as multiple recurring C. difficile infections (mrCDI), are rapidly becoming more common. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 3, 2017 Category: International Medicine & Public Health Source Type: news

C. Diff Infections Are Falling, Thanks To Better Cleaning And Fewer Antibiotics
The bacterium C. difficile causes one of the most common infections in hospitals and nursing homes. After climbing for decades, the rate of new infections is now falling.(Image credit: David Phillips/Science Source) (Source: NPR Health and Science)
Source: NPR Health and Science - June 29, 2017 Category: Consumer Health News Authors: Angus Chen Source Type: news

Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis
This Meta-analysis (9,056,241 patient-days and 159 estimates of incidence ratios) found that antibiotic stewardship programmes reduced the incidence of infections and colonisation with multidrug-resistant bacteria and C difficile infections in hospital inpatients. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - June 20, 2017 Category: Consumer Health News Source Type: news

Association of Adverse Events With Antibiotic Use in Hospitalized Patients
In this study, a review of medical records of 1488 patients for 30 days after antibiotic (AB) initiation noted 298 (20%) experienced at least 1 AB-associated ADR. Also 56 (20%) non –clinically indicated AB regimens were associated with an ADR, including 7 cases of C difficile infection. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - June 20, 2017 Category: Consumer Health News Source Type: news

Preventing Recurrent CDI: New, Old, and Really Old Strategies Preventing Recurrent CDI: New, Old, and Really Old Strategies
Three new studies assess strategies for preventing recurrence of C difficile infection in patients at risk.Society for Healthcare Epidemiology of America (SHEA) (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 15, 2017 Category: Consumer Health News Tags: Infectious Diseases Viewpoint Source Type: news

Fecal transplants prevent diarrhea for up to two years
Researchers from the University of Alabama found all donated bacteria species persist in all recipients for at least six months. The procedure is approved for recurrent C.difficile infections.. (Source: the Mail online | Health)
Source: the Mail online | Health - June 14, 2017 Category: Consumer Health News Source Type: news

Donor microbes persist 2 years after fecal transplant to treat C. difficile infection
(University of Alabama at Birmingham) University of Alabama at Birmingham researchers have made the first direct demonstration that fecal donor microbes remained in recipients for months or years after a transplant to treat the diarrhea and colitis caused by recurrent Clostridium difficile infections -- a serious and stubborn cause of diarrhea after an antibiotic treatment for some other illness. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 13, 2017 Category: Infectious Diseases Source Type: news

Seres begins Phase III trial of SER-109 to treat recurrent C. difficile infection
US-based microbiome therapeutics developer Seres Therapeutics has begun a Phase III clinical trial of SER-109 for the treatment of patients suffering from multiple recurrent clostridium difficile (C. difficile) infection. (Source: Drug Development Technology)
Source: Drug Development Technology - June 12, 2017 Category: Pharmaceuticals Source Type: news

Antibiotic-Associated Adverse Events Common Antibiotic-Associated Adverse Events Common
As many as 20% of hospitalized patients prescribed antibiotics experienced an adverse drug event, including Clostridium difficile or multidrug-resistant organism infection, a new study found.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 12, 2017 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news

Preventing recurrence of Clostridium difficile infection: bezlotoxumab: Evidence summary [ES13]
This evidence summary discusses two similar randomised controlled trials that compared the efficacy and safety of a single dose of bezlotoxumab 10 mg/kg with placebo for preventing the recurrence of C difficile infection in people taking usual standard-of-care antibiotics (usually metronidazole or vancomycin). A summary to inform local decision-making is included. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - June 9, 2017 Category: Consumer Health News Source Type: news

C difficile Infection: An Orthopaedic Surgeon's Guide C difficile Infection: An Orthopaedic Surgeon's Guide
Find out what there is to know about the prevention and treatment strategies for this infection related to orthopedic procedures.Journal of the American Academy of Orthopaedic Surgeons (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 31, 2017 Category: Consumer Health News Tags: Orthopaedics Journal Article Source Type: news

Ridinilazole Versus Vancomycin for Initial C. Difficile Infection Ridinilazole Versus Vancomycin for Initial C. Difficile Infection
Ridinilazole, a novel, targeted-spectrum antimicrobial, was found to be non-inferior to vancomycin for treating initial Clostridium difficile infection (CDI), according to a study funded by the maker of ridinilazole (Summit Therapeutics, Abingdon, U.K.) and Wellcome Trust.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 24, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Optimal use of Rapid Diagnostics in Infection Control and Prevention
Clinical laboratories have implemented rapid diagnostic tests (RDTs) for the identification of bacterial pathogens, with subsequent improvements in antimicrobial stewardship, but these tests may also have a role in infection prevention. Early identification of pathogens by RDTs should allow faster implementation of infection prevention strategies with the goal of reducing transmission. In this review, we assess the use of RDTs as an infection control tool by exploring their role in screening, as well as diagnosis, of methicillin-resistant Staphylococcus aureus (MRSA), carbapenem-resistant gram-negative organisms, Clostridi...
Source: Clinical Microbiology Newsletter - May 20, 2017 Category: Microbiology Authors: Mary Elizabeth Sexton, Jesse T. Jacob Source Type: news

Clostridium difficile: To Test or Not to Test (and How?) Clostridium difficile: To Test or Not to Test (and How?)
New data help clinicians select appropriate patients for C diff testing.Society for Healthcare Epidemiology of America (SHEA) (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 18, 2017 Category: Consumer Health News Tags: Infectious Diseases Viewpoint Source Type: news

Can A 'Poop Transplant' Change Your Weight?
In this study, 70 patients received FMTs to treat C. diff infections. Twenty-five of the patients received stool from donors who had normal BMIs; 30 received stool from overweight donors, and 15 received stool from obese donors. [5 Ways Gut Bacteria Affect Your Health] In the six months before the transplants, many of the patients lost weight, which is common with C. diff infections, said lead study author Dr. Monika Fischer, a gastroenterologist and an assistant professor of clinical medicine at Indiana University School of Medicine. But in the year after the transplants, the researchers didn’t observe statistically...
Source: Healthy Living - The Huffington Post - May 16, 2017 Category: Consumer Health News Source Type: news

Synthetic Biologics ’ SYN-004 secures FDA breakthrough therapy status
Synthetic Biologics has secured breakthrough therapy designation for SYN-004 (ribaxamase) from the US Food and Drug Administration (FDA) to treat Clostridium difficile infection (CDI). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 14, 2017 Category: Pharmaceuticals Source Type: news

Maryland company wins FDA fast-track status for superbug drug
Rockville-based Synthetic Biologics Inc. received fast-track status from the Food and Drug Administration for a drug candidate that might prevent one of the most common health care-associated infections in the U.S. Clostridium difficile, often referred to as C. diff, sickens more than 450,000 patients in the U.S. every year and causes $1.5 billion in additional health care costs annually. The drug candidate SYN-004 is an oral enzyme designed to protect the gut microbiome against C. diff and the… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 12, 2017 Category: Pharmaceuticals Authors: Tina Reed Source Type: news

Maryland company wins FDA fast-track status for superbug drug
Rockville-based Synthetic Biologics Inc. received fast-track status from the Food and Drug Administration for a drug candidate that might prevent one of the most common health care-associated infections in the U.S. Clostridium difficile, often referred to as C. diff, sickens more than 450,000 patients in the U.S. every year and causes $1.5 billion in additional health care costs annually. The drug candidate SYN-004 is an oral enzyme designed to protect the gut microbiome against C. diff and the… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 12, 2017 Category: Biotechnology Authors: Tina Reed Source Type: news

This Rockville company just won breakthrough status for a drug to prevent hospital infection
Rockville-based Synthetic Biologics Inc. received fast-track status from the Food and Drug Administration for a drug candidate that might prevent one of the most common health care-associated infections in the U.S. Clostridium difficile, often referred to as C. diff, sickens more than 450,000 patients in the U.S. every year and causes $1.5 billion in additional health care costs annually. The drug candidate SYN-004 is an oral enzyme designed to protect the gut microbiome against C. diff and the… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 12, 2017 Category: Pharmaceuticals Authors: Tina Reed Source Type: news

Fecal Microbiota Transplantation for Recurrent C. difficile Fecal Microbiota Transplantation for Recurrent C. difficile
How do different donor products compare overall and in terms of resolution of C. difficile infection?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 4, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Study of bacteria's DNA fingerprint suggests it could be spreading via food distribution
Foods should be investigated as a potential source of spread of Clostridium difficile, according to research. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 22, 2017 Category: Science Source Type: news

Bacteria's DNA fingerprint suggests it could be spreading via food distribution
Foods should be investigated as a potential source of spread of Clostridium difficile, according to research. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 22, 2017 Category: Science Source Type: news

Study of bacteria's DNA fingerprint suggests it could be spreading via food distribution
(European Society of Clinical Microbiology and Infectious Diseases) Foods should be investigated as a potential source of spread of Clostridium difficile, according to research presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases.. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 21, 2017 Category: Infectious Diseases Source Type: news

C difficile-Associated Diarrhea in the Oncology Patient C difficile-Associated Diarrhea in the Oncology Patient
What is the best treatment option for C difficile in patients with cancer?Journal of Oncology Practice (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - April 20, 2017 Category: Intensive Care Tags: Hematology-Oncology Journal Article Source Type: news

Clostridium difficile infections linked to higher death rates if infection recurs
(European Society of Clinical Microbiology and Infectious Diseases) Two presentations at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) show that repeated infection with the bacterium Clostridium difficile (C. difficile), which causes stomach upsets and diarrhoea, is linked to higher death rates, as well as having a significant impact on health services in terms of cost and hospital beds occupied. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 20, 2017 Category: Infectious Diseases Source Type: news

Rebiotix's RBX2660 demonstrates positive outcome in Phase II trial for C. diff. infection
Microbiome company Rebiotix has reported a positive outcome for RBX2660 from the Phase II PUNCH clinical trial for the prevention of recurrent Clostridium difficile (C. diff.) infection. (Source: Drug Development Technology)
Source: Drug Development Technology - April 11, 2017 Category: Pharmaceuticals Source Type: news

Roche launches cobas Liat PCR System with four assays into CE-markets
Roche today announced the CE-IVD launch of the cobas ® Liat® PCR System with four assays including first 20 minute real-time PCR nucleic acid test to detect Clostridium difficile (C. diff). (Source: Roche Media News)
Source: Roche Media News - April 3, 2017 Category: Pharmaceuticals Source Type: news

Roche launches cobas Liat PCR System with four assays into CE-markets
Roche today announced the CE-IVD launch of the cobas ® Liat® PCR System with four assays including first 20 minute real-time PCR nucleic acid test to detect Clostridium difficile (C. diff). (Source: Roche Investor Update)
Source: Roche Investor Update - April 3, 2017 Category: Pharmaceuticals Source Type: news

Would You Drink A Probiotic With The Gut Bacteria Of Elite Athletes?
Can sneaker endorsements, cereals, protein powders or electrolyte cocktails get any of us closer to the peak level performance of our favorite athletes? Despite billions in sales, the answer is probably no. But how about an elite athlete’s biology? With 100 trillion cells in the human body, bacteria outnumber our own human cells 2 to 1, and bacteria in our gut affect all our key organ functions. The microbiome plays a role in our health, development and wellness, including endurance, recovery and mental aptitude. What if we could tap the gut bacteria of elite athletes to produce customized probiotics ― and what if ...
Source: Healthy Living - The Huffington Post - April 2, 2017 Category: Consumer Health News Source Type: news

HONEY: Is this ancient medicinal food the key to fighting deadly drug-resistant infections?
(Natural News) Exotic honey can be used as a powerful alternative when treating one of the deadliest infections in the U.S. today. A report published in the International Journal of Antimicrobial Agents confirms that exotic honey can battle antibiotic-resistant infections, like Clostridium difficile. Interestingly, C.difficile is caused by an overdose of antibiotics. Two researchers from Elisabeth-TweeSteden Hospital’s Department... (Source: NaturalNews.com)
Source: NaturalNews.com - March 31, 2017 Category: Consumer Health News Source Type: news